Diabetes Care, Vol 16, Issue 6 902-910, Copyright © 1993 by American Diabetes Association

ARTICLES

Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients

A Gottsater, M Landin-Olsson, P Fernlund, A Lernmark and G Sundkvist
Department of Medicine, University of Lund, Malmo General Hospital, Sweden.

OBJECTIVE--To determine the effects of islet cell antibodies on beta-cell function during the first 3 yr after diagnosis in type II diabetic patients. RESEARCH DESIGN AND METHODS--beta-cell function in type II diabetic patients with (n = 11, 50 +/- 5 yr of age) and without (n = 10, 52 +/- 4 yr of age) ICA was followed prospectively and compared with beta-cell function in type I adult diabetic patients (n = 17, 37 +/- 5 yr of age) and in healthy control subjects (n = 34, age 45 +/- 3 yr). beta-cell function was evaluated as fasting C-peptide, 1 + 3 min C-peptide after intravenous glucose, and delta C-peptide after glucagon. RESULTS--Fasting C-peptide was equal in type II diabetic patients with ICA (0.30 +/- 0.03 nM) and type I diabetic patients (0.24 +/- 0.03 nM) at diagnosis, and decreased (P < 0.05) during 3 yr in these groups but not in type II diabetic patients without ICA. At diagnosis, type II diabetic patients with ICA showed a 1 + 3 min C-peptide (0.92 +/- 0.17 nM) lower (P < 0.001) than control subjects but higher (P < 0.05) than type I diabetic patients (0.53 +/- 0.11 nM). After 1 yr, 1 + 3 min C-peptide in type II diabetic patients with ICA had decreased (P < 0.05) to 0.18 +/- 0.11 nM and was equal to type I diabetic patients (0.38 +/- 0.10 nM). delta C-peptide after glucagon was equally impaired in type II diabetic patients with ICA (0.38 +/- 0.06 nM) and type I diabetic patients (0.35 +/- 0.11 nM) at diagnosis. After 3 yr, type II diabetic patients with ICA had fasting C-peptide of 0.09 +/- 0.04 nM, 1 + 3 min C-peptide of 0.18 +/- 0.10 nM, and delta C-peptide after glucagon of 0.20 +/- 0.09 nM, values equal to type I diabetic patients but lower (P < 0.01) than in type II diabetic patients without ICA, whose values remained unchanged; fasting C-peptide of 0.97 +/- 0.17 nM, 1 + 3 min C-peptide of 2.31 +/- 0.50 nM, and delta C-peptide after glucagon of 1.76 +/- 0.28 nM. CONCLUSIONS--In patients considered type II diabetic with ICA, beta-cell function progressively decreased after diagnosis, and after 3 yr was similar to type I diabetic patients, whereas beta-cell function in type II diabetic patients without ICA was unchanged.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74. [Full Text] [PDF]

				Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J., January 1, 2007; 28(1): 88 - 136. [Full Text] [PDF]

				S. Fourlanos, C. Perry, M. S. Stein, J. Stankovich, L. C. Harrison, and P. G. Colman A Clinical Screening Tool Identifies Autoimmune Diabetes in Adults Diabetes Care, May 1, 2006; 29(5): 970 - 975. [Abstract] [Full Text] [PDF]

				G. Stenstrom, A. Gottsater, E. Bakhtadze, B. Berger, and G. Sundkvist Latent Autoimmune Diabetes in Adults: Definition, Prevalence, {beta}-Cell Function, and Treatment Diabetes, December 1, 2005; 54(suppl_2): S68 - S72. [Abstract] [Full Text] [PDF]

				I. Vauhkonen, L. Niskanen, M. Knip, L. M. Mykkanen, S. Haffner, M. Uusitupa, and M. Laakso Subtle hyperproinsulinaemia characterises the defective insulin secretory capacity in offspring of glutamic acid decarboxylase antibody-positive patients with latent autoimmune diabetes mellitus in adults Eur. J. Endocrinol., August 1, 2005; 153(2): 265 - 273. [Abstract] [Full Text] [PDF]

				P. Narendran, E. Estella, and S. Fourlanos Immunology of type 1 diabetes QJM, August 1, 2005; 98(8): 547 - 556. [Full Text] [PDF]

				J. P. Palmer, G. A. Fleming, C. J. Greenbaum, K. C. Herold, L. D. Jansa, H. Kolb, J. M. Lachin, K. S. Polonsky, P. Pozzilli, J. S. Skyler, et al. C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve {beta}-Cell Function: Report of an ADA Workshop, 21-22 October 2001 Diabetes, January 1, 2004; 53(1): 250 - 264. [Abstract] [Full Text] [PDF]

				J. P. Palmer and I. B. Hirsch What's in a Name: Latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes Diabetes Care, February 1, 2003; 26(2): 536 - 538. [Full Text] [PDF]

				G. Stenstrom, B. Berger, H. Borg, P. Fernlund, J. S. Dorman, and G. Sundkvist HLA-DQ Genotypes in Classic Type 1 Diabetes and in Latent Autoimmune Diabetes of the Adult Am. J. Epidemiol., November 1, 2002; 156(9): 787 - 796. [Abstract] [Full Text] [PDF]

				H. Borg, A. Gottsater, P. Fernlund, and G. Sundkvist A 12-Year Prospective Study of the Relationship Between Islet Antibodies and {beta}-Cell Function At and After the Diagnosis in Patients With Adult-Onset Diabetes Diabetes, June 1, 2002; 51(6): 1754 - 1762. [Abstract] [Full Text] [PDF]

				P. Vague and L. Nguyen Rationale and Methods for the Estimation of Insulin Secretion in a Given Patient: From Research to Clinical Practice Diabetes, February 1, 2002; 51(90001): S240 - 244. [Abstract] [Full Text] [PDF]

				P. Pozzilli and U. Di Mario Autoimmune Diabetes Not Requiring Insulin at Diagnosis (Latent Autoimmune Diabetes of the Adult): Definition, characterization, and potential prevention Diabetes Care, August 1, 2001; 24(8): 1460 - 1467. [Abstract] [Full Text] [PDF]

				H. Borg, A. Gottsater, M. Landin-Olsson, P. Fernlund, and G. Sundkvist High Levels of Antigen-Specific Islet Antibodies Predict Future {beta}-Cell Failure in Patients with Onset of Diabetes in Adult Age J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3032 - 3038. [Abstract] [Full Text] [PDF]

				E. H. Hathout, W. Thomas, M. El-Shahawy, F. Nahab, and J. W. Mace Diabetic Autoimmune Markers in Children and Adolescents With Type 2 Diabetes Pediatrics, June 1, 2001; 107(6): e102 - 102. [Abstract] [Full Text] [PDF]

				B Wesche, E Jaeckel, C Trautwein, H Wedemeyer, A Falorni, H Frank, A von zur Muhlen, M-P Manns, and G Brabant Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C Gut, March 1, 2001; 48(3): 378 - 383. [Abstract] [Full Text] [PDF]

				C. Törn, M. Landin-Olsson, A. Lernmark, J. P. Palmer, H. J. Arnqvist, G. Blohmé, F. Lithner, B. Littorin, L. Nyström, B. Scherstén, et al. Prognostic Factors for the Course of {beta} Cell Function in Autoimmune Diabetes J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4619 - 4623. [Abstract] [Full Text]

				A. Carlsson, G. Sundkvist, L. Groop, and T. Tuomi Insulin and Glucagon Secretion in Patients with Slowly Progressing Autoimmune Diabetes (LADA) J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 76 - 80. [Abstract] [Full Text]

				H. Borg, P. Fernlund, and G. Sundkvist Measurement of antibodies against glutamic acid decarboxylase 65 (GADA): two new 125I assays compared with [35S]GAD 65-ligand binding assay Clin. Chem., May 1, 1997; 43(5): 779 - 785. [Abstract] [Full Text] [PDF]

				G. Tyden, F. P. Reinholt, G. Sundkvist, and J. Bolinder Recurrence of Autoimmune Diabetes Mellitus in Recipients of Cadaveric Pancreatic Grafts N. Engl. J. Med., September 19, 1996; 335(12): 860 - 863. [Full Text] [PDF]